WO1997036575A1 - Nouvelles compositions laxatives et leur procede de fabrication - Google Patents
Nouvelles compositions laxatives et leur procede de fabrication Download PDFInfo
- Publication number
- WO1997036575A1 WO1997036575A1 PCT/FR1997/000567 FR9700567W WO9736575A1 WO 1997036575 A1 WO1997036575 A1 WO 1997036575A1 FR 9700567 W FR9700567 W FR 9700567W WO 9736575 A1 WO9736575 A1 WO 9736575A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical compositions
- acid
- monosodium
- sodium bicarbonate
- phosphate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Definitions
- the present invention relates to the field of therapeutic chemistry and more particularly to that of pharmacotechnology.
- compositions with laxative properties the main characteristic of which is to contain an effervescent mixture releasing carbon dioxide in a rapid and progressive manner.
- the invention relates specifically to new pharmaceutical compositions intended for the rectal route capable of causing, by chemical reaction, the active principles in contact with the humidity present in the rectal ampoule, significant and rapid gassing.
- French Patent No. 788,198 (Waldenmeyer JG) has already described a process for producing effervescent suppositories which offers the possibility of giving off carbon dioxide in the nascent state under the action of humidity, heat or any other another cause and in which the raw materials releasing by mixing this acid are coated as protection in a fatty substance which thus avoids a premature chemical reaction and thereby protects against decomposition.
- These suppositories however contain in their mass hydrophilic ingredients which allow biological fluids to penetrate into the mass and allow the start of the chemical reaction which causes the physiological effect.
- the first solution consists in increasing the quantity of reactive active ingredients in order to increase the volume of carbon dioxide released.
- the size of a suppository quickly reaches a limit, and therefore it is not possible to incorporate more active ingredients into it without jeopardizing the preservation and homogeneity of the suppositories.
- the other solution consists in incorporating into the mass of the pharmaceutical composition intended for the rectal route, another acid constituent more reactive than potassium acid tartrate and having all the necessary guarantees of local tolerance and the absence of toxicological risk, the limit remains in the need not to have a too brutal CO 2 release.
- the invention therefore consists of pharmaceutical compositions intended for the rectal route, formed from an effervescent mixture consisting of an alkali metal bicarbonate and a compound with a specific acid reaction chosen from the group consisting of monosodium or monopotassium phosphate, monosodium citrate , pyroglutamic acid and glutamic acid, in combination or in mixture with one or more diluents or vehicles suitable for producing a pharmaceutical form intended for the rectal route.
- an effervescent mixture consisting of an alkali metal bicarbonate and a compound with a specific acid reaction chosen from the group consisting of monosodium or monopotassium phosphate, monosodium citrate , pyroglutamic acid and glutamic acid, in combination or in mixture with one or more diluents or vehicles suitable for producing a pharmaceutical form intended for the rectal route.
- the effervescent formulation requires the presence of an alkaline element capable of easily releasing carbon dioxide by chemical reaction with an acidic compound.
- an alkaline element capable of easily releasing carbon dioxide by chemical reaction with an acidic compound.
- the reaction is much slower and rarely complete in a relatively short period of time.
- the choice of the acidic compound requires compliance with two conditions. This acid compound must not be irritating or toxic on the one hand, and it must not trigger an excessively violent or too rapid effervescence reaction in contact with the alkaline agent.
- the pka of the acid compound used and on the other hand the solubility in water or the biological media of the acid compound there is in the first place the pka of the acid compound used and on the other hand the solubility in water or the biological media of the acid compound.
- a compound such as benzoic phthalimide or succinimide due to their low solubility in water causes only a limited and delayed release of carbon dioxide. It
- compositions intended for rectal use denote in the first place suppositories made of a natural or synthetic fatty matrix, and also rectal capsules made of gelatin. Other forms of administration by the rectal route, solid or pasty, can also be envisaged.
- the acid compound content will be that which roughly also corresponds in molar form to the formulation defined in the prior patent application in France No. 94.11913 in the name of the Applicant, namely 1, 150 g of acid tartrate potassium for 0.700 g of sodium bicarbonate per adult suppository, i.e. between 1.15 g and 1.20 g preferably, 1.184 g for monosodium phosphate, between 1.25 and 1.30 g and preferably 1, 2847 g for the sodium citrate, or, for a diacid substance such as glutamic acid, between 0.85 and 0.90 g and preferably 0.878 g and for pyroglutamic acid between 0.85 and 0.90 g and preferably 0.889 g. Under these conditions the mixture is likely to release a volume of CO 2 measured with the Bernard calcimeter, at atmospheric pressure, of the order of 100 to 120 ml for a suppository in the space of 20 minutes.
- a subject of the invention is also a process for producing pharmaceutical compositions intended for the rectal route, which consists in incorporating an acid reaction salt chosen from monosodium phosphate, monopotassium phosphate, monosodium citrate, pyroglutamic acid and glutamic acid and an alkali metal bicarbonate to a hydrophilic excipient then to an opacifying agent and this mixture is introduced into a fatty excipient fusible in the vicinity of body temperature.
- an acid reaction salt chosen from monosodium phosphate, monopotassium phosphate, monosodium citrate, pyroglutamic acid and glutamic acid and an alkali metal bicarbonate
- the hydrophilic excipient is preferably a vegetable or animal lecithin, such as for example soy lecithin or egg yolk lecithins.
- the opacifying agent is a powdery mineral product, insoluble in the hydrophilic excipient and in the fatty excipient.
- the opacifying agent will be an aluminum silicate, a magnesium silicate, a titanium oxide or a silica.
- the fatty excipient is a melting point fat situated at around 40 ° C. such as cocoa butter, shea butter, Illipé butter or mixtures thereof or else a polyalcohol stearate such as a glyceryl stearate or polyethylene glycol semi-synthetic or synthetic, the melting point of which lies in this temperature range like the polyethylene glycol stearates marketed under the name Labrafil and the semi-synthetic glycerides described in the French Pharmacopoeia 10 th Edition and marketed by the name Estaram , Suppose ...
- the test consists of verifying the operation of the installation of Bernard's calcimeter.
- This test begins with stoichiometric calculation to determine the amount of saccharin necessary to use without changing the amount of bicarbonate contained in the industrial formula.
- Bicar 0.7 g. 0.250 mm sieve
- the CO 2 release is derisory in comparison with the quantities of active principle predicted by the stoichiometric calculation.
- the manufacturing of the suppos proved difficult because it was necessary to heat up to 60 ° C to fill the cells on the one hand and the mass was too pasty and grainy on the other hand. This difficulty may be due to the small amount of suppocire used.
- the table below shows the combined results of the different dosages of anhydrous monosodium phosphate suppositories compared to the 2 g suppositories manufactured industrially and the 2 g suppositories manufactured at the GALENIQUE Laboratory.
- compositions according to the invention are provided.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Control Of Heat Treatment Processes (AREA)
- Control Of Electric Motors In General (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69729618T DE69729618T2 (de) | 1996-04-01 | 1997-03-28 | Abführmittel und verfahren zu deren herstellung |
CA002223265A CA2223265C (fr) | 1996-04-01 | 1997-03-28 | Nouvelles compositions laxatives et leur procede de fabrication |
PL97323624A PL189874B1 (pl) | 1996-04-01 | 1997-03-28 | Sposób wytwarzania kompozycji farmaceutycznych przeznaczonych do podawania doodbytniczego |
US08/973,452 US6461638B1 (en) | 1996-04-01 | 1997-03-28 | Laxative compositions and method for making same |
AT97919442T ATE269693T1 (de) | 1996-04-01 | 1997-03-28 | Abführmittel und verfahren zu deren herstellung |
EP97919442A EP0833610B1 (fr) | 1996-04-01 | 1997-03-28 | Compositions laxatives et leur procede de fabrication |
BR9702160A BR9702160A (pt) | 1996-04-01 | 1997-03-28 | Novas composições laxativas e processo de fabricação das mesmas |
NO19975526A NO321425B1 (no) | 1996-04-01 | 1997-12-01 | Fremgangsmate for fremstilling av laksativpreparater |
HK99101263A HK1016080A1 (en) | 1996-04-01 | 1999-03-26 | Novel laxative compositions and method for making same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR96/04041 | 1996-04-01 | ||
FR9604041A FR2746643B1 (fr) | 1996-04-01 | 1996-04-01 | Nouvelles compositions laxatives et leur procede de fabrication |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997036575A1 true WO1997036575A1 (fr) | 1997-10-09 |
Family
ID=9490763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1997/000567 WO1997036575A1 (fr) | 1996-04-01 | 1997-03-28 | Nouvelles compositions laxatives et leur procede de fabrication |
Country Status (16)
Country | Link |
---|---|
US (1) | US6461638B1 (fr) |
EP (1) | EP0833610B1 (fr) |
KR (1) | KR100563811B1 (fr) |
CN (1) | CN1129423C (fr) |
AT (1) | ATE269693T1 (fr) |
BR (1) | BR9702160A (fr) |
CA (1) | CA2223265C (fr) |
DE (1) | DE69729618T2 (fr) |
DK (1) | DK0833610T3 (fr) |
ES (1) | ES2224240T3 (fr) |
FR (1) | FR2746643B1 (fr) |
HK (1) | HK1016080A1 (fr) |
MX (1) | MX9709329A (fr) |
NO (1) | NO321425B1 (fr) |
PL (1) | PL189874B1 (fr) |
WO (1) | WO1997036575A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7687075B2 (en) * | 2003-11-19 | 2010-03-30 | Salix Pharmaceuticals, Ltd. | Colonic purgative composition with soluble binding agent |
US8545902B2 (en) | 2010-12-15 | 2013-10-01 | Nicholas Lion | Dosage forms of plant-derived cathartics |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR5391M (fr) * | 1965-11-04 | 1967-10-23 | ||
GB1212704A (en) * | 1967-11-21 | 1970-11-18 | Prodotti Antibiotici Spa | Vaginal suppositories |
FR2105111A1 (fr) * | 1970-09-28 | 1972-04-28 | Sogeras | |
JPS60224614A (ja) * | 1984-04-23 | 1985-11-09 | Kao Corp | 発泡性グリセリン坐剤 |
EP0423015A1 (fr) * | 1989-10-13 | 1991-04-17 | L'oreal | Composition effervescente pour les ongles |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3764668A (en) * | 1970-09-30 | 1973-10-09 | Interx Research Corp | Compositions of salts of salicylamide |
US4451454A (en) * | 1981-06-16 | 1984-05-29 | Wong Dennis W | Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals |
DE3521994A1 (de) * | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
US5468504A (en) * | 1990-12-21 | 1995-11-21 | Laboratoires Glaxo S.A. | Effervescent pharmaceutical compositions |
IE72090B1 (en) * | 1991-07-05 | 1997-03-12 | Merck Sharp & Dohme | Aromatic compounds pharmaceutical compositions containing them and their use in therapy |
-
1996
- 1996-04-01 FR FR9604041A patent/FR2746643B1/fr not_active Expired - Fee Related
-
1997
- 1997-03-28 AT AT97919442T patent/ATE269693T1/de not_active IP Right Cessation
- 1997-03-28 PL PL97323624A patent/PL189874B1/pl unknown
- 1997-03-28 CN CN97190652A patent/CN1129423C/zh not_active Expired - Fee Related
- 1997-03-28 US US08/973,452 patent/US6461638B1/en not_active Expired - Lifetime
- 1997-03-28 DK DK97919442T patent/DK0833610T3/da active
- 1997-03-28 WO PCT/FR1997/000567 patent/WO1997036575A1/fr active IP Right Grant
- 1997-03-28 KR KR1019970708758A patent/KR100563811B1/ko not_active IP Right Cessation
- 1997-03-28 ES ES97919442T patent/ES2224240T3/es not_active Expired - Lifetime
- 1997-03-28 BR BR9702160A patent/BR9702160A/pt not_active Application Discontinuation
- 1997-03-28 EP EP97919442A patent/EP0833610B1/fr not_active Expired - Lifetime
- 1997-03-28 CA CA002223265A patent/CA2223265C/fr not_active Expired - Fee Related
- 1997-03-28 DE DE69729618T patent/DE69729618T2/de not_active Expired - Lifetime
- 1997-12-01 NO NO19975526A patent/NO321425B1/no not_active IP Right Cessation
- 1997-12-01 MX MX9709329A patent/MX9709329A/es unknown
-
1999
- 1999-03-26 HK HK99101263A patent/HK1016080A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR5391M (fr) * | 1965-11-04 | 1967-10-23 | ||
GB1212704A (en) * | 1967-11-21 | 1970-11-18 | Prodotti Antibiotici Spa | Vaginal suppositories |
FR2105111A1 (fr) * | 1970-09-28 | 1972-04-28 | Sogeras | |
JPS60224614A (ja) * | 1984-04-23 | 1985-11-09 | Kao Corp | 発泡性グリセリン坐剤 |
EP0423015A1 (fr) * | 1989-10-13 | 1991-04-17 | L'oreal | Composition effervescente pour les ongles |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Week 8551, Derwent World Patents Index; AN 85-320778, XP002021616 * |
T. HAKATA ET AL.: "EFFECTS OF BASES AND ADDITIVES ON RELEASE OF CARBON DIOXIDE FROM EFFERVESCENT SUPPOSITORIES", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 41, no. 2, February 1993 (1993-02-01), TOKYO (JP), pages 351 - 356, XP000354420 * |
T. HAKATA ET AL.: "METHODS OF EVALUATION OF RELEASE OF CARBON DIOXIDE FROM EFFERVESCENT SUPPOSITORIES", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 41, no. 2, February 1993 (1993-02-01), TOKYO (JP), pages 346 - 351, XP000354419 * |
Also Published As
Publication number | Publication date |
---|---|
CN1129423C (zh) | 2003-12-03 |
KR100563811B1 (ko) | 2006-09-22 |
ES2224240T3 (es) | 2005-03-01 |
ATE269693T1 (de) | 2004-07-15 |
DE69729618D1 (de) | 2004-07-29 |
KR19990022279A (ko) | 1999-03-25 |
FR2746643A1 (fr) | 1997-10-03 |
PL189874B1 (pl) | 2005-10-31 |
NO975526D0 (no) | 1997-12-01 |
BR9702160A (pt) | 1999-03-02 |
US6461638B1 (en) | 2002-10-08 |
DK0833610T3 (da) | 2004-10-25 |
DE69729618T2 (de) | 2005-07-14 |
EP0833610A1 (fr) | 1998-04-08 |
FR2746643B1 (fr) | 1998-06-12 |
CA2223265C (fr) | 2005-02-08 |
CA2223265A1 (fr) | 1997-10-09 |
CN1194579A (zh) | 1998-09-30 |
NO975526L (no) | 1998-01-29 |
EP0833610B1 (fr) | 2004-06-23 |
HK1016080A1 (en) | 1999-10-29 |
MX9709329A (es) | 1998-08-30 |
PL323624A1 (en) | 1998-04-14 |
NO321425B1 (no) | 2006-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI110353B (fi) | Menetelmä farmaseuttisen valmisteen valmistamiseksi pore- ja/tai hajoamistabletin tai pikarakeiden muodossa | |
EP0233853B1 (fr) | Couples effervescents, compositions effervescentes d'antagonistes H2 de l'histamine les contenant et leur préparation | |
BE904899A (fr) | Compositions therapeutiques flottantes a degagement progressif. | |
FR2601876A1 (fr) | Composition pharmaceutique hydrosoluble contenant de la n-acetyl-cysteine et de l'acide citrique | |
CA2727109C (fr) | Mannitol orodispersible | |
US4937076A (en) | Chewable aspirin and buffering material tablet and method for producing same | |
CA2480824A1 (fr) | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline | |
JP2008542305A (ja) | 配送システム | |
KR20010043408A (ko) | 활성 성분인 가티플록사신, 또는 약제학적으로 적합한이의 염 또는 이의 수화물을 재현 가능하게 방출시키는경구용 의약 제제 | |
RU2706727C2 (ru) | Шипучие композиции и способы их получения и применения | |
RU2427376C2 (ru) | Композиции s-аденозилметионина для перорального применения | |
WO1997036575A1 (fr) | Nouvelles compositions laxatives et leur procede de fabrication | |
JP4364869B2 (ja) | 咀嚼性カプセルの製造方法 | |
EP0806949B1 (fr) | Nouvelle composition pharmaceutique contenant la trimebutine et son procede de preparation | |
CA2178220C (fr) | Nouveau procede de fabrication de suppositoires | |
EP0741564B1 (fr) | Nouveau procede de fabrication de suppositoires | |
FR2476485A1 (fr) | Nouveau procede d'enrobage d'au moins un principe actif medicamenteux, les nouveaux medicaments ainsi obtenus, et les compositions les renfermant | |
FR2720944A1 (fr) | Composition thérapeutique ou diététique sous forme de gel médicamenteux pour l'administration à des animaux de compagnie. | |
DE69729729T2 (de) | Arzneimittel zur anwendung im mund | |
JPH10130140A (ja) | グミ製剤の製造方法 | |
JPS61207329A (ja) | 親水性物質を充てんした軟カプセル剤 | |
JPH0150205B2 (fr) | ||
EP3233060B1 (fr) | Libération maîtrisée de substances actives | |
FR3123652A1 (fr) | Procede de modification d’amidon par traitement hydro-thermique, amidon obtenu par ce procede et ses utilisations | |
CA1234761A (fr) | Comprime d'aspirine a mastiquer contenant un agent tampon et methode de production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97190652.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CA CN KR MX NO PL US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997919442 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2223265 Country of ref document: CA Ref document number: 2223265 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970708758 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1997919442 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970708758 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08973452 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997919442 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970708758 Country of ref document: KR |